4,758 results on '"Nukiwa, T"'
Search Results
2. Mycobacterium avium genotype is associated with the therapeutic response to lung infection
3. Nationwide prospective registry of idiopathic interstitial pneumonias with central multidisciplinary diagnosis in Japan (JIPS Registry): Analysis of disease progression
4. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
5. Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
6. A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405
7. Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan.
8. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells
9. Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry.
10. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival
11. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000
12. The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes
13. THE PHARMACOKINETICS OF BIBF 1120 ALONE OR IN COMBINATION WITH PIRFENIDONE IN JAPANESE PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF): 799
14. Long-term safety of Prolastin®-C, an alpha1-proteinase inhibitor, in Japanese patients with alpha1-antitrypsin deficiency.
15. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR .
16. Pirfenidone Delays the Prescription of Concomitant Drugs in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Japanese Phase III Clinical Trial
17. Association between mycobacterial genotypes and disease progression in Mycobacterium avium pulmonary infection
18. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis
19. Papillary adenoma of type II pneumocytes might have malignant potential
20. O1–137 - PHASEII Study of S-1 with Irinotecan Combination Therapy for EGFR-Mutated NSCLC Resistant to EGFR-TKI: NJLCG0804
21. [Central Pattern Generators for Breathing and Gait and Possible Medical Application of Oriental BodyWork: Access to Extrapyramidal and Body Trunk Movement System Through Breathing Methods].
22. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis
23. IgG reactive to CTL-directed epitopes of self-antigens is either lacking or unbalanced in atopic dermatitis patients
24. Bilateral pneumothoraces with multiple bullae in a patient with asymptomatic bronchiolitis obliterans 10 years after bone marrow transplantation
25. Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals
26. Towards an Effective Gene Therapy for Idiopathic Pulmonary Fibrosis*: Anti-inflammation, Antifibrosis, and Regeneration
27. Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma
28. Effect of Hepatocyte Growth Factor on Lung Injury and Development of Clinical Application*
29. P2.14-52 The Results from Plasma EGFR Mutation Analysis in NEJ026 Study
30. Follow-up of patients with superior vena cava syndrome by functional analysis of radionuclide venography
31. Hepatocyte growth factor in bronchoalveolar lavage fluids and cells in patients with inflammatory chest diseases of the lower respiratory tract: detection by RIA and in situ hybridization.
32. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
33. Alpha 1-antitrypsin-deficient variant Siiyama (Ser53[TCC] to Phe53[TTC]) is prevalent in Japan. Status of alpha 1-antitrypsin deficiency in Japan.
34. Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung.
35. The Effect of Pirfenidone on the Prescription of Antibiotics and Antitussive Drugs in Patients With Idiopathic Pulmonary Fibrosis: A Post Hoc Exploratory Analysis of Phase III Clinical Trial.
36. Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
37. A phase II study of first-line afatinib for patients aged 75 or older with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan study group trial NEJ027
38. Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)
39. P1.01-20 Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009)
40. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
41. P2.03-010 Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC
42. P2.03-021 A Phase I Study Evaluating the Combination of Afatinib, Carboplatin and Pemetrexed after Failure of 1st Generation EGFR-TKIs
43. P3.01-035 Post-Marketing Observational Study of Japanese Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Treated with Daily Afatinib (Final Report)
44. Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
45. Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy.
46. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study.
47. Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.
48. Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice.
49. Mesenchymal Stem Cells in Cancer Therapy.
50. NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.